A24 IPF: CLINICAL STUDIES, THERAPEUTICS, AND MORE I: Prospective Single Arm Open Labeled Multicenter Trial For Safety And Efficacy Of Recombinant Human Thrombomodulin For Acute Exacerbation In Idiopathic Interstitial Pneumonias (setup Trial)

[Materials and Methods] AE-IIPs in rhTM arm (n=39) were diagnosed with the criteria of Japanese Respiratory Society (ERJ 2010) from 2014 to 2016 in 6 institutes and treated with intravenous rhTM (380 U/kg/day) for 6 days from the diagnosis in addition to the conventional therapy with 0.5-1 mg/kg dai...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Main Authors: Arai, T, Kida, H, Ogata, Y, Marumo, S, Matsuoka, H, Gohma, I, Mori, M, Yamamoto, S, Sugimoto, C, Tachibana, K, Hamasaki, T, Akira, M, Inoue, Y
Format: Article
Language:English
Subjects:
Pneumonia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Materials and Methods] AE-IIPs in rhTM arm (n=39) were diagnosed with the criteria of Japanese Respiratory Society (ERJ 2010) from 2014 to 2016 in 6 institutes and treated with intravenous rhTM (380 U/kg/day) for 6 days from the diagnosis in addition to the conventional therapy with 0.5-1 mg/kg daily of prednisolone (PSL) and intravenous methylprednisolone dosing 500-1000mg daily for three successive days. Weights were derived from propensity score modeling of the probability of rhTM treatment as a function of potential confounders including IPF/Non-IPF, long term oxygen therapy (LTOT) and PSL administration at stable state, HRCT pattern {diffuse/non-diffuse pattern defined by Akira (AJRCCM 2008)}, PaO2/FiO2 ratio and lactate dehydrogenase (LDH) at AE.
ISSN:1073-449X
1535-4970